Anti-CD19 CAR T cells were among the last decade’s scientific breakthroughs, achieving remarkable remissions in patients with B cell leukemias and lymphomas. Now, the engineered cell therapies are traversing disease indications into autoimmunity and resolving disease symptoms in patients with systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis.¹

中文翻译：

---

治疗交叉点：将 CD19 CAR T 细胞的益处从癌症扩展到自身免疫

抗 CD19 CAR T 细胞是过去十年的科学突破之一，使 B 细胞白血病和淋巴瘤患者取得了显着的缓解。现在，工程细胞疗法正在将疾病适应症转变为自身免疫，并解决系统性红斑狼疮 (SLE)、特发性炎症性肌炎和系统性硬化症患者的疾病症状。¹